Figure 3

The changes in the serum or plasma levels of G-CSF (a), GM-CSF (b), eotaxin (c), FGF-2 (d), VEGF (e), soluble CD40 ligand (f), fractalkine (g), MIP-β (h), glycer-AGEs (i) and sRAGE (j) by the treatment with glimepiride. Open bars indicate "before treatment" and solid bars indicate "after treatment". *p < 0.05 versus before treatment. G-CSF = granulocyte colony-stimulating factor, GM-CSF = granulocyte macrophage-colony stimulating factor, FGF = fibroblast growth factor, VEGF = vascular endothelial growth factor, MIP = macrophage inflammatory protein, glycer-AGE = glyceraldehyde-derived advanced glycation end products, sRAGE = soluble receptor for advanced glycation end products.